About the Company
merrimack is a fully integrated biopharmaceutical company that views cancer as a complex engineering challenge. through systems biology, which brings together the fields of biology, computing and engineering, merrimack aims to decrease uncertainty in drug development and clinical validation, and move discovery efforts beyond trial and error. such an approach has the potential to make individualized treatment of patients a reality. merrimack's first commercial product, onivydetm (irinotecan liposome injection), was approved by the u.s. fda on october 22, 2015. with four additional candidates in clinical studies, several in preclinical development and multiple biomarkers designed to support patient selection, merrimack is building one of the most robust oncology pipelines in the industry. for more information, please visit merrimack's website at www.merrimack.com or connect on twitter at @merrimackpharma.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $MACK News
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) is definitely on the radar of hedge funds investors who own 35% of the company
Key Insights Significantly high institutional ownership implies Merrimack Pharmaceuticals' stock price is sensitive ...
Merrimack Reports Full Year 2023 Financial Results
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its full year 2023 financial results for the period ended ...
Merrimack Pharmaceuticals to Hold Meeting on Corporate Dissolution
Merrimack Pharmaceuticals plans to hold a special shareholder meeting to approve a plan for a corporate dissolution. The biopharmaceutical company added this would be followed by a distribution of ...
Merrimack Pharma (MACK) Earnings Dates & Reports
View upcoming earnings forecasts and in-depth analysis of company forecasts.
Merrimack Pharmaceuticals Inc MACK
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Merrimack Reports Full Year 2023 Financial Results
Merrimack reported a gain on sale of assets for the year ended December 31, 2023, of $0.1 million compared to $0.4 million for the same period in 2022. General and administrative expenses for the year ...
Merrimack Pharmaceuticals, Inc.
Merrimack Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with ...
Merrimack Pharmaceuticals, Inc. Common Stock (MACK)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green highlights the top performing ETF by % change in the past ...
Merrimack Pharmaceuticals Inc MACK
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Merrimack Pharmaceuticals, Inc. Common Stock (MACK)
Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...
Loading the latest forecasts...